Last reviewed · How we verify
inclisiran sodium injection
Inclisiran sodium injection, marketed by Novartis Pharmaceuticals, is a novel therapeutic currently in the market with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the competitive landscape, where multiple established therapies are already vying for market share.
At a glance
| Generic name | inclisiran sodium injection |
|---|---|
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (PHASE4)
- A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. (PHASE3)
- Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events (PHASE3)
- Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes (PHASE3)
- Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia (PHASE3)
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (PHASE3)
- Inclisiran Effectiveness in China: a Pragmatic Randomized Trial (PHASE4)
- Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- inclisiran sodium injection CI brief — competitive landscape report
- inclisiran sodium injection updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI